Leadership Team

Chief Financial Officer

Ralf joined Fortis as the Chief Financial Officer in December 2023. Prior to joining Fortis, he served as President of Shared Services and CFO for the US operations of Eurofins. In his role at Eurofins, Ralf built a strong platform that played a pivotal role in positioning Eurofins as a leading player in the US testing markets. He also has a proven track record of integrating acquisitions.

Before joining Eurofins in 2006, Ralf served as the Director of Finance of Siegwerk Ink Packaging, a German-based global manufacturer of printing ink for the packaging and publication industries. Before that he held various positions in Banking, Treasury and Corporate Controlling.

Ralf holds a bachelor's degree in business administration in Finance from the Frankfurt School of Finance & Management and an Executive MBA from the University of Iowa.

Chief Commercial Officer

Eric joined Fortis as the Chief Commercial Officer in 2023. He is responsible for Global Business Development, Marketing, Product Management, and Go-To-Market Strategy. Prior to Fortis, he served as an operating partner for various private equity firms supporting investments in life sciences tools. Before that, he spent 9 years at Danaher Corporation (NYSE: DHR), most recently as GM of Labcyte. He also worked in the pharmaceutical industry with Forest Laboratories/Allergan, and in academia at Fort Hays State University.

Education: BS and MS from University of Illinois

Chief Legal & Compliance Officer

Lori joined Fortis as the first General Counsel & Corporate Secretary in May of 2022. Since that time, Lori has expanded her role to include Chief Human Resource Officer, Chief Compliance Officer, and Head of the Quality & Regulatory Affairs organization.

Prior to joining Fortis, Lori served as Associate General Counsel at Exact Sciences Corporation (NASDAQ:EXAS) where she led legal support for Clinical Operations, R&D and the Multi-Cancer division. Prior to Exact Sciences, Lori spent 11 years at Hologic, Inc. (NASDAQ:HOLX) as Senior Director, Senior Corporate Counsel supporting the Operations & Shared Services, Diagnostics and International divisions with their legal and compliance needs. Lori has over 22 years of broad legal and compliance experience with over 14 years in various sectors of the life science industry.

Education: BA in English and Psychology from Boston College; JD from Suffolk University Law School

Chief Business Officer

Fred is responsible for corporate development, strategy, innovation, and operational excellence. He was previously a life sciences & healthcare investor at Summit Partners, a leading private equity firm with more than $40 billion of capital under management. Prior to that, he advised on M&A transactions for public and private companies and institutional investors at Deloitte Corporate Finance. He began his career as a high school AP Calculus and AP Statistics teacher and as a member of Teach For America.

Education: BS University of Florida (summa cum laude), MBA from Harvard Business School

General Manager, Nanomaterial Solutions

Jeff has over 10 years of experience in product management, sales, and marketing functions and has served technologies ranging from life sciences consumables to RF components for defense and telecommunications. As General Manager for Nanomaterials Solutions, Jeff draws from his tenure at nanoComposix and his background in physical chemistry to serve the unique challenges of nanomaterials manufacturing and integration.

Education: BS Chemistry from University of Washington

General Manager, Diagnostic Solutions

David was a co-founder and the CEO of International Point of Care (IPOC) with 40 years of experience in the diagnostic industry at both large public companies and entrepreneurial new ventures. Prior to the acquisition of IPOC in 2008, David served in executive leadership roles with Nanogen, Spectral Diagnostics' and Aruna Biomedical, David began his career in the life science industry during a 12-year tenure at AMF Medical Products. David has experience and expertise in various organizational disciplines including, Manufacturing, Quality, Regulatory, and Business Development.

Education: Paramedic, Texas DPH - Scott and White Hospital, BS in Physiology from Texas State University and his MBA from The University of Texas, San Antonio.

Interim General Manager, Antibody Solutions

Lisa became Interim General Manager of the Antibody Solutions business at Fortis in January 2024, having joined Fortis in October 2023 as Director of the Life Science portfolio. Prior to Fortis, she spent 14 years at Thermo Fisher Scientific (NYSE:TMO) most recently as Senior Product and Business Development Manager for the Protein and Cellular Analysis business. Lisa has a background in biotechnology including a Ph.D. in Plant Molecular Virology

Education: BSc Life Science, University of Dundee, Scotland. BSc (Hon.) Biotechnology, Abertay University. Ph.D. Plant Molecular Biology, University of Dundee, Scotland.

General Manager, Cell & Gene Therapy Solutions

Rodney became General Manager of the Cell & Gene Therapy business at Fortis in January 2024, having joined Fortis in August 2022 as VP of Global M&A. Prior to Fortis, he served in senior leadership roles, including serving in roles such as CEO, board member and senior corporate development executive, over the past 25 years at companies such as Life Technologies, EVOTEC, AYOXXA, Fluidigm (now Standard Biotools) and as a consultant and advisor to private equity, venture capital and life science tools businesses and investors.

Education: BA from Rice University

Senior Advisor

John has over 12 years of experience in the antibody manufacturing space as the Chief Executive at Bethyl Laboratories, Inc. He previously served as the Section Chief of Hematology and Laboratory Director at Sadler Clinic, in the Houston area.

Education: BS in Animal Science from Texas A&M, MD from Texas A&M University Health Science Center, Residency & Fellowship training in Internal Medicine & Hematology from Baylor College of Medicine.

Senior Advisor

Nearly 20 years in the nanoparticle field as the CEO/Founder at nanoComposix.

Education: PhD in Applied Physics from Rice University, BSc in Physics and Computer Science from the University of British Columbia

Executive Director & Chairman of the Board

David P. King is is a respected senior healthcare executive who operates with a strong emphasis on deeply understanding the healthcare industry, strategic planning, "playing the long game," and staying ahead of rapidly evolving industry trends and challenges. He uses the insights gained in his 20+ year healthcare career in providing strategic and operational advice to industry stakeholders.

Mr. King most recently served as executive chair and CEO of Laboratory Corporation of America Holdings (Labcorp). Under his leadership, Labcorp transformed from a pure-play U.S. testing laboratory into a leading global life sciences company — tripling in size through a combination of organic growth and strategic acquisitions, entering the Fortune 500, and being named to Fortune's List of World's Most Admired Companies. It is now the world's largest clinical laboratory and second-largest drug development business. In 2019, Forbes named Mr. King to its list of America's Most Innovative Leaders.

Prior to joining Labcorp, Mr. King was partner at Hogan & Hartson LLP (now Hogan Lovells) where he was a key leader in the firm's healthcare fraud and abuse practice, representing national healthcare companies in investigations and litigation. Mr. King was also an Assistant U.S. Attorney for the District of Maryland.

Mr. King's board service includes non-executive chair of Privia Health (NASDAQ:PRVA); nonexecutive chair of ZimVie (NASDAQ:ZIMV); and board member of several privately-held companies. Mr. King's community service includes serving as a board member of Novant Health, a multi-state integrated health system; and on the advisory board and executive committee of Duke University's Robert J. Margolis, MD, Center for Health Policy. Mr. King previously served on the board of Cardinal Health (NYSE: CAH), a Fortune 20 healthcare company; PATH, a nonprofit global health organization (board chair from 2018 to 2021); The Emily K Center, a college-readiness center founded by Duke Men's Basketball Coach Mike Krzyzewski; and the American Clinical Laboratory Association, (board chair from 2010 to 2014). Mr. King holds a bachelor's degree, cum laude, from Princeton University and a Juris Doctor, cum laude, from the University of Pennsylvania Law School.

Darren joined Summit Partners in 2013 and focuses primarily on the healthcare & life sciences sector. Darren's current board directorships include InnovaCare HealthPartners, Leon Medical Centers, LifeStance Health (NASDAQ: LFST), Paradigm Outcomes, PharmScript, Sound Physicians, TurningPoint Healthcare Solutions, U.S. Renal Care, VaxCare and Veranex.

Prior to Summit, Darren was a Managing Partner with SV Life Sciences, where he focused on healthcare services, healthcare information technology and pharmaceutical services. Prior to SV Life Sciences, Darren was Cofounder and President of two companies—ClinCare and PharmaStar. Previously, he was a healthcare consultant for Accenture.

Darren holds an AB in government from Harvard College and an MBA from the Wharton School of the University of Pennsylvania. He serves on the board of directors for Beth Israel Deaconess Medical Center and Combined Jewish Philanthropies and Friends of the IDF.

Julie Coletti is EVP, Chief Legal & Regulatory Officer at Align Technology, Inc. (NASDAQ: ALGN), a leading global medical device company and the world’s largest 3D printing company. Align designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software and is driving the evolution in digital dentistry through the Align Digital Platform. Julie advises the Align Board and Executive Committee, drives business-focused strategies and outcomes to support rapid growth, geographic expansion and business model transformation and leads a team of over 1,000 legal, regulatory and quality professionals. Prior to joining Align, Julie served as the Vice President and Global General Counsel for Danaher Corporation’s Dental Platform (NYSE: DHR) and before that as Vice President, Bayer HealthCare, Chief Legal Officer for Bayer Radiology and Interventional.

Ross joined Summit Partners in 2009 and focuses primarily on the healthcare & life sciences sector. His investment and board experience includes Abode Healthcare, DMG Practice Management Solutions, My Dentist, Paradigm Outcomes, PharmScript, Sound Physicians, TurningPoint Healthcare Solutions, U.S. Renal Care and VaxCare.

Previously, Ross worked at the Center for Medicare and Medicaid Innovation and in Cowen and Company’s Health Care Investment Banking Group, where he focused on M&A transactions as well as public and private offerings.

Ross holds a BA in economics and history from Bowdoin College and an MBA from the Wharton School at the University of Pennsylvania.